Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 311


Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Prud'homme C, Deschamps F, Allorant A, Massard C, Hollebecque A, Yevich S, Ngo-Camus M, Gravel G, Nicotra C, Michiels S, Scoazec JY, Lacroix L, Solary E, Soria JC, De Baere T, Tselikas L.

Eur J Cancer. 2018 Sep 14;103:108-119. doi: 10.1016/j.ejca.2018.08.003. [Epub ahead of print]


Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.

Mir O, Azaro A, Merchan J, Chugh R, Trent J, Rodon J, Ohnmacht U, Diener JT, Smith C, Yuen E, Oakley GJ 3rd, Le Cesne A, Soria JC, Benhadji KA, Massard C.

Eur J Cancer. 2018 Sep 12;103:88-97. doi: 10.1016/j.ejca.2018.08.012. [Epub ahead of print]


ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.

Peltola KJ, Bono P, Jones RH, Vjaters E, Nykänen P, Vuorela A, Oksala R, Pohjanjousi P, Mustonen MVJ, Fizazi K, Massard C.

Eur Urol Focus. 2018 Sep 4. pii: S2405-4569(18)30241-4. doi: 10.1016/j.euf.2018.08.022. [Epub ahead of print]


A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.


Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.

Koeppel F, Bobard A, Lefebvre C, Pedrero M, Deloger M, Boursin Y, Richon C, Chen-Min-Tao R, Robert G, Meurice G, Rouleau E, Michiels S, Massard C, Scoazec JY, Solary E, Soria JC, André F, Lacroix L.

Cancer J. 2018 Jul/Aug;24(4):153-162. doi: 10.1097/PPO.0000000000000322.


Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic.

Patrikidou A, Maroun P, Patard JJ, Baumert H, Albiges L, Massard C, Loriot Y, Escudier B, Di Palma M, Arfi-Rouche J, Rocher L, Merabet Z, Bossi A, Fizazi K, Blanchard P.

Clin Transl Radiat Oncol. 2018 Jul 6;12:28-33. doi: 10.1016/j.ctro.2018.07.001. eCollection 2018 Aug.


Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression.

Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2018 Sep;101:160-164. doi: 10.1016/j.ejca.2018.06.005. Epub 2018 Jul 30.


First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer.

Massard C, Azaro A, Soria JC, Lassen U, Le Tourneau C, Sarker D, Smith C, Ohnmacht U, Oakley G, Patel BKR, Yuen ESM, Benhadji KA, Rodon J.

Ann Oncol. 2018 Jul 28. doi: 10.1093/annonc/mdy244. [Epub ahead of print]


Randomized Phase II Study of Akt Blockade With or Without Ipatasertib in Abiraterone-Treated Patients With Metastatic Prostate Cancer With and Without PTEN Loss.

de Bono JS, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel P, Maslyar DJ, Jinga V.

Clin Cancer Res. 2018 Jul 23. pii: clincanres.0981.2018. doi: 10.1158/1078-0432.CCR-18-0981. [Epub ahead of print]


First molecular evidence of Babesia caballi and Theileria equi infections in horses in Cuba.

Díaz-Sánchez AA, Pires MS, Estrada CY, Cañizares EV, Del Castillo Domínguez SL, Cabezas-Cruz A, Rivero EL, da Fonseca AH, Massard CL, Corona-González B.

Parasitol Res. 2018 Oct;117(10):3109-3118. doi: 10.1007/s00436-018-6005-5. Epub 2018 Jul 23.


Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.

Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, Wallmark JM, Keam B, Delord JP, Aggarwal R, Gould M, Yang P, Keefe SM, Piha-Paul SA.

Ann Oncol. 2018 Aug 1;29(8):1807-1813. doi: 10.1093/annonc/mdy232.


Occurrences of Ornithocoris toledoi (Cimicidae) on a free-range chicken farm in the state of Rio de Janeiro, Brazil.

Pires MS, Luz HR, Peckle M, Silva CBD, Vitari GLV, Costa RLD, Graciosa MG, Santos HA, Faccini JLH, Massard CL.

Rev Bras Parasitol Vet. 2018 Jun 11. pii: S1984-29612018005006102. doi: 10.1590/S1984-296120180036. [Epub ahead of print]


Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience.

Besle S, Schultz E, Hollebecque A, Varga A, Baldini C, Martin P, Postel-Vinay S, Bahleda R, Gazzah A, Michot JM, Marabelle A, Angevin E, Armand JP, Ribrag V, Soria JC, Massard C.

Eur J Cancer. 2018 Jul;98:17-22. doi: 10.1016/j.ejca.2018.04.019. Epub 2018 May 30.


Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos PG, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C.

J Clin Oncol. 2018 May 7:JCO2018782292. doi: 10.1200/JCO.2018.78.2292. [Epub ahead of print]


Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M.

Tumori. 2018 Mar 1:300891618763215. doi: 10.1177/0300891618763215. [Epub ahead of print]


Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.


Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.


Development and validation of a duplex real-time PCR assay for the diagnosis of equine piroplasmosis.

Lobanov VA, Peckle M, Massard CL, Brad Scandrett W, Gajadhar AA.

Parasit Vectors. 2018 Mar 2;11(1):125. doi: 10.1186/s13071-018-2751-6.


Durvalumab in urothelial cancers.

Lavaud P, Hamilou Z, Loriot Y, Massard C.

Expert Rev Anticancer Ther. 2018 Apr;18(4):311-318. doi: 10.1080/14737140.2018.1443812. Epub 2018 Mar 5.


Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.


Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.


Comparison of heat shock protein 70 kDa and 18S rDNA genes for molecular detection and phylogenetic analysis of Babesia vogeli from whole blood of naturally infected dogs.

Paulino PG, Pires MS, Silva CBD, Peckle M, Costa RLD, Vitari GLV, Abreu APM, Almosny NRP, Massard CL, Santos HA.

Ticks Tick Borne Dis. 2018 Mar;9(3):556-562. doi: 10.1016/j.ttbdis.2018.01.013. Epub 2018 Feb 1.


Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.


Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

Louvel G, Bahleda R, Ammari S, Le Péchoux C, Levy A, Massard C, Le Pavec J, Champiat S, Deutsch E.

Eur Respir J. 2018 Jan 4;51(1). pii: 1701737. doi: 10.1183/13993003.01737-2017. Print 2018 Jan. No abstract available.


[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma].

Bernard-Tessier A, Bonnet C, Lavaud P, Gizzi M, Loriot Y, Massard C.

Bull Cancer. 2018 Feb;105(2):140-145. doi: 10.1016/j.bulcan.2017.10.030. Epub 2017 Dec 28. Review. French.


[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer].

Vignot S, André T, Caux C, Bouleuc C, Evrard S, Gonçalves A, Lacroix M, Magné N, Massard C, Mazeron JJ, Orbach D, Rodrigues M, Thariat J, Wislez M, L'Allemain G, Bay JO.

Bull Cancer. 2018 Jan;105(1):6-14. doi: 10.1016/j.bulcan.2017.11.006. Review. French.


Molecular characterization of Theileria equi in horses from the state of Rio de Janeiro, Brazil.

Peckle M, Pires MS, Silva CBD, Costa RLD, Vitari GLV, Senra MVX, Dias RJP, Santos HA, Massard CL.

Ticks Tick Borne Dis. 2018 Feb;9(2):349-353. doi: 10.1016/j.ttbdis.2017.11.011. Epub 2017 Nov 28.


First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors.

Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O.

Clin Cancer Res. 2018 Apr 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7.


A polymorphous bullous dermatosis.

Drahy F, Hotz C, Ortonne N, Ghoufi L, Grootenboer-Mignot S, Massard C, Perrin MP, Chosidow O, Ingen-Housz-Oro S.

Lancet Oncol. 2017 Dec;18(12):e776. doi: 10.1016/S1470-2045(17)30461-8. No abstract available.


Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.


Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors.

Bahleda R, Le Deley MC, Bernard A, Chaturvedi S, Hanley M, Poterie A, Gazzah A, Varga A, Touat M, Deutsch E, Massard C, Van De Velde H, Hollebecque A, Sallansonnet-Froment M, Ricard D, Taillia H, Angevin E, Ribrag V, Soria JC.

Invest New Drugs. 2018 Aug;36(4):619-628. doi: 10.1007/s10637-017-0531-3. Epub 2017 Nov 2.


Molecular and Morphological Characterization of a Brazilian Lineage of Plasmodium ( Novyella) Unalis in Turdus Spp. (Passeriformes) of the Atlantic Forest, with Remarks on New Hosts and High Genetic Variation.

Tostes R, Dias RJP, de Oliveira L, Senra MVX, Massard CL, D'Agosto M.

J Parasitol. 2018 Feb;104(1):70-78. doi: 10.1645/16-189. Epub 2017 Nov 8.


Are phase I trials safe for older patients?

Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A.

J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. Review.


Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Guida A, Albiges L, Derosa L, Loriot Y, Massard C, Fizazi K, Escudier B.

Clin Genitourin Cancer. 2017 Dec;15(6):e1081-e1088. doi: 10.1016/j.clgc.2017.07.015. Epub 2017 Aug 12.


Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.


Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.


Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.


[The breakthrough of personalized medicine, new hopes and new challenges].

Flippot R, Massard C, Auclin E, Azria D, Bourien H, Rochigneux P, Schernberg A, Verlingue L, Zafrani L, Vignot S.

Bull Cancer. 2017 Sep;104(9):735-743. doi: 10.1016/j.bulcan.2017.07.003. Epub 2017 Aug 12. Review. French.


Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence.

Dercle L, Ammari S, Bateson M, Durand PB, Haspinger E, Massard C, Jaudet C, Varga A, Deutsch E, Soria JC, Ferté C.

Sci Rep. 2017 Aug 11;7(1):7952. doi: 10.1038/s41598-017-08310-5.


Patient-reported tolerability of adverse events in phase 1 trials.

Henon C, Lissa D, Paoletti X, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S.

ESMO Open. 2017 Jun 23;2(2):e000148. doi: 10.1136/esmoopen-2016-000148. eCollection 2017.


Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2017 Mar 7. pii: S2405-4569(17)30065-2. doi: 10.1016/j.euf.2017.02.017. [Epub ahead of print] Review.


Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.

Shore ND, Tammela TL, Massard C, Bono P, Aspegren J, Mustonen M, Fizazi K.

Eur Urol Focus. 2017 Feb 14. pii: S2405-4569(17)30024-X. doi: 10.1016/j.euf.2017.01.015. [Epub ahead of print]


Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.

Fizazi K, Massard C, Bono P, Kataja V, James N, Tammela TL, Joensuu H, Aspegren J, Mustonen M.

Eur Urol Focus. 2017 Dec;3(6):606-614. doi: 10.1016/j.euf.2017.01.010. Epub 2017 Feb 27.


RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.


Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.

Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M, Wollmer P, Trägårdh E, Bondesson E, Edenbrandt L, Fizazi K, Bjartell A.

Eur Urol Focus. 2016 Dec;2(5):547-552. doi: 10.1016/j.euf.2016.01.005. Epub 2016 Feb 3.


Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey.

Bultijnck R, Surcel C, Ploussard G, Briganti A, De Visschere P, Fütterer J, Ghadjar P, Giannarini G, Isbarn H, Massard C, Sooriakumaran P, Valerio M, van den Bergh R, Ost P.

Eur Urol Focus. 2016 Dec;2(5):514-521. doi: 10.1016/j.euf.2016.02.009. Epub 2016 Mar 5.


Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

Hollebecque A, Bahleda R, Faivre L, Adam J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga A, Gazzah A, Ileana E, Gharib M, Angevin E, Malekzadeh K, Massard C, Soria JC, Spano JP.

Eur J Cancer. 2017 Aug;81:81-89. doi: 10.1016/j.ejca.2017.05.021. Epub 2017 Jun 12.


Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Massard C, Chi KN, Castellano D, de Bono J, Gravis G, Dirix L, Machiels JP, Mita A, Mellado B, Turri S, Maier J, Csonka D, Chakravartty A, Fizazi K.

Eur J Cancer. 2017 Aug;81:242. doi: 10.1016/j.ejca.2017.05.003. Epub 2017 Jun 10. No abstract available.


Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.

Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V.

Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9.


Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.

Matias M, Le Teuff G, Albiges L, Guida A, Brard C, Bacciarelo G, Loriot Y, Massard C, Lassau N, Fizazi K, Escudier B.

Eur J Cancer. 2017 Jul;79:185-192. doi: 10.1016/j.ejca.2017.04.015. Epub 2017 May 13.


Supplemental Content

Loading ...
Support Center